Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Active Biotech AB and Teva Pharmaceutical Industries Ltd Announce Enrollment of First Patient in Third Phase II Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis

Wednesday, 6 Mar 2013 08:00am EST 

Active Biotech AB announced with Teva Pharmaceutical Industries Ltd the enrollment of the first patient in the CONCERTO study - the third Phase III placebo-controlled study designed to evaluate the efficacy, safety and tolerability of once-daily oral laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS). The primary outcome measure of CONCERTO will be confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS). The multinational, randomized, double blind placebo-controlled study will aim to enroll approximately 1,800 patients at over 300 sites. Along with the primary endpoint of time to confirmed disability progression, the study will also examine the impact of laquinimod on endpoints such as percentage change in brain volume and other clinical and MRI markers of disease activity. 

Company Quote

0.4 +2.41%
18 Dec 2014